Several studies have shown that targeting macrophages improved cancer outcome, either by depleting them with clodronate liposome injection for instance, blocking the phagocytosis pathway, inhibiting their recruitment (CXCR2/CCL2 pathway blocking), targeting CD47, or by reprogramming them toward an anti-tumoral phenotype (11, 25, 52, 53, 57, 59). The gene discussed is CXCR2; the disease is cancer.